The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...